TRO-02 / TriOar - LARVOL DELTA

TRO-02, a conditionally activated EGFR-targeting ADC incorporating TROCADTM and TROSIGTM platforms, shows enhanced tumor selectivity and potent efficacy (AACR 2026) - "TRO-02 is a DAR8-type ADC generated by conjugating a potent topoisomerase I inhibitor to panitumumab via a cleavable, stable, and hydrophilic TROSIGTM linker. Furthermore, pharmacokinetic analysis in rats demonstrated favorable PK properties (t1/2 = 4.47 days, AUC = 163.52 day·μg/mL, CL = 25.05 mL/day/kg, Vd = 0.08 L/kg at 4 mg/kg), indicating high in vivo stability and low clearance. Collectively, these findings demonstrate that TRO-02 is a conditionally activated EGFR-targeting ADC with improved therapeutic index, achieving potent antitumor efficacy while minimizing on-target/off-tumor toxicity."

ADC • Clinical • Colorectal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ANXA1